Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 11 January 2026 - 12 January 2026

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

New York, Jan 12, 2026, 16:34 (EST) — After-hours Alnylam Pharmaceuticals shares dropped in late Monday trading after the RNA interference drugmaker unveiled a new five-year plan and provided early 2026 sales guidance, along with preliminary figures for 2025. The stock slipped roughly 6.7% to $370.91. The company unveiled its “Alnylam 2030” initiative, aiming for “leadership in ATTR amyloidosis” and “sustained, profitable growth.” It’s targeting total revenue compound annual growth above 25% through 2030, along with a non-GAAP operating margin near 30%. For 2026, combined net product revenue is expected between $4.9 billion and $5.3 billion, spanning AMVUTTRA, ONPATTRO, GIVLAARI,
12 January 2026
·····
Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

New York, January 12, 2026, 15:41 ET — Regular session Shares of Arcutis Biotherapeutics dropped 8.7% on Monday, slipping $2.46 to $25.76, following the company’s update on its 2026 priorities. The dermatology drugmaker set a $455 million to $470 million target for net product sales in its ZORYVE franchise. The stock hit a session low of $25.51 during trading. The message is crucial as Arcutis hits a stage where investors demand more than just rapid script growth — they want evidence it can scale without another cash drain. One marketed franchise can sustain a company, until it can’t. It also
12 January 2026
·····
Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

New York, January 12, 2026, 14:42 EST — Regular session. Merck & Co shares slipped $1.26, or 1.1%, to $109.27 in Monday afternoon trading. The stock has fluctuated between $111.45 and $108.95 today. Investors want clarity on Merck’s next steps beyond Keytruda and its legacy blockbusters. The upcoming J.P. Morgan Healthcare Conference promises to bring that question into sharp focus. Biotech shares opened the week lower, with the SPDR S&P Biotech ETF slipping 2.1%, according to Barron’s. The report noted hopes for major deals, like a possible Merck bid for Revolution Medicines, but no announcements had emerged by late morning.
12 January 2026
·····
Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

New York, Jan 12, 2026, 2:38 PM EST — Regular session Shares of Johnson & Johnson climbed roughly 2.3% to $209.03 on Monday, pushing the stock near the high end of its trading range after new oncology data came out over the weekend. This move is crucial as major drugmakers face mounting pressure to demonstrate lasting growth ahead of earnings season, with healthcare executives filling up their schedules for updates. For J&J, oncology remains a focal point, and Rybrevant has recently caught investors’ attention. Traders often see early cancer data as a fast indicator of pipeline momentum, despite approvals being
12 January 2026
·····
AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

New York, January 12, 2026, 13:31 EST — Regular session AbbVie Inc shares slipped Monday following news of a new collaboration with China’s RemeGen to co-develop an experimental solid-tumor drug, as the company ramps up efforts to expand its cancer portfolio via licensing deals. By 1:30 p.m. EST, AbbVie was down 0.6% at $218.81. (Reuters) Investors are focused on how fast AbbVie can transform its oncology pipeline into a real growth driver instead of just another distant promise. The company said the drug could create new combination opportunities with its antibody-drug conjugates, or ADCs — targeted cancer therapies linking an
12 January 2026
·····
Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus

Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus

New York, Jan 12, 2026, 11:53 EST — Regular session Shares of Recursion Pharmaceuticals climbed Monday following the release of an updated investor presentation via a Form 8-K filing. The Nasdaq-traded stock gained 4.4%, reaching $4.87 late morning, putting the company’s market cap near $2.1 billion. (SEC) The filing comes as executives and investors gather in San Francisco for the J.P. Morgan Healthcare Conference, a week known for sparking deal talk and shifting outlooks for small biotech firms. “The need to take big swings becomes more pressing,” Jeremy Meilman, JPMorgan’s global co-head of healthcare investment banking, told the Financial Times.
12 January 2026
·····
Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus

Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus

New York, Jan 12, 2026, 11:17 EST — Regular session Shares of Revolution Medicines (RVMD) slipped around 1.8% to $116.51 in early Monday trading, pulling back from a 52-week peak amid fresh analyst notes following a rollercoaster week of takeover rumors. The stock fluctuated between $113.47 and $119.58 during the session, pegging the company’s market cap at about $23 billion. The retreat follows a Wall Street Journal story revealing Merck’s ongoing talks to acquire Revolution in a deal pegged between $28 billion and $32 billion. The report suggests an announcement might arrive later this month but notes discussions remain tentative,
12 January 2026
····
Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

New York, Jan 12, 2026, 10:58 EST — Regular session Eli Lilly’s stock climbed in early trading Monday following the announcement that the drugmaker and Nvidia plan to invest roughly $1 billion over five years in a joint research lab focused on accelerating drug discovery. The news comes as executives and investors gather at the J.P. Morgan Healthcare Conference in San Francisco, where buzz around drug pipelines can quickly shift valuations in a sector still relying on a handful of blockbuster drugs. AI is increasingly woven into the narrative, particularly for firms eager to prove they can go beyond their
12 January 2026
·······
Teva stock jumps after $500 million Royalty Pharma deal as investors eye JPM update

Teva stock jumps after $500 million Royalty Pharma deal as investors eye JPM update

New York, Jan 12, 2026, 10:13 ET — Regular session Teva Pharmaceutical Industries’ U.S.-listed shares jumped roughly 4% to $33.29 in Monday morning trading. The boost came after the drugmaker unveiled new funding for an experimental vitiligo treatment and offered a glimpse of its year-end outlook. This move is crucial as Teva aims to prove to investors that its growth story is both genuine and well-funded, even as it ramps up focus on branded medicines and a late-stage pipeline amid a hefty debt load. The timing is notable, arriving right before a crucial investor week when major pharmaceutical companies take
12 January 2026
·····
NovaBay Pharmaceuticals (NBY) stock slides premarket after 102% surge — dilution risk back on radar

NovaBay Pharmaceuticals (NBY) stock slides premarket after 102% surge — dilution risk back on radar

New York, January 12, 2026, 05:15 EST — Premarket NovaBay Pharmaceuticals, Inc. shares slipped roughly 10% in early Monday trading, falling to $17.21 after finishing Friday at $19.16. This dip comes after a notable surge in the lightly traded stock on the NYSE American. https://stockanalysis.com/stocks/nby/ Friday’s surge was extreme, even for a microcap. Shares closed up 102.5%, swinging between $9.69 and $19.95, on roughly 10 million shares changing hands, according to StockAnalysis data. https://stockanalysis.com/stocks/nby/history/ This is crucial now, as the stock has morphed into a momentum play within just a few sessions. Such trades hinge heavily on share availability. With
12 January 2026
·····
GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

London, January 12, 2026, 08:41 GMT — Regular session Shares of GSK plc edged down 0.03% to 1,885.5 pence early Monday in London, after fluctuating between 1,870.5 and 1,885.5 pence during the session. The annual J.P. Morgan Healthcare Conference takes place January 12–15 in San Francisco. According to the agenda, GSK is scheduled for a 7:30 a.m. Pacific slot on Tuesday, followed by AstraZeneca later that morning. The San Francisco meetings this week often set the initial tone for big drugmakers each year — focusing on pipelines, pricing, and occasionally deals. Investors are on the lookout for any news that
12 January 2026
······
Novo Nordisk stock: Amazon starts selling Wegovy pill, putting next week in focus

Novo Nordisk stock: Amazon starts selling Wegovy pill, putting next week in focus

Copenhagen, January 11, 2026, 23:22 CET — Market closed Novo Nordisk (NOVOb.CO) shares climbed 3% to 381.45 Danish crowns on Friday after Amazon Pharmacy announced it will offer the drugmaker’s Wegovy weight-loss pill through insurance coverage as well as a cash-pay option. The U.S.-listed ADRs (NVO) closed 2.6% higher at $58.81. (Reuters) Novo’s new distribution channel is crucial as the company seeks to steady sentiment following a rough 2025. In July, the stock plunged almost 30% in one day after it lowered its 2025 sales forecast. Since then, investors have been quick to sell on any sign of weakening U.S.
11 January 2026
······
1 … 16 17 18 19 20 … 56

Stock Market Today

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

7 February 2026
Ashtead shares closed Friday at 4,936p, up 1.09%, after the company bought 88,872 shares under its repurchase program. The group is set to shift its primary listing to New York on March 2, pending court approval, and will be removed from the FTSE UK index the same day. Ashtead paid a half-year dividend of 37.5 U.S. cents per share on Friday.
Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

7 February 2026
Beazley shares closed flat at 1,236 pence Friday as BlackRock disclosed a 6.55% stake and Vanguard reported 5.02%. Wellington Management cut its holding below 5%. The disclosures follow Zurich Insurance’s possible takeover offer of up to 1,335 pence per share, with a Feb. 16 deadline for a firm bid.
Go toTop